Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

AgomAb Therapeutics NV

NASDAQ: AGMB · Life Sciences · 7 alerts · CIK 2020932

Share price
$5.97Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AgomAb Therapeutics NV filings on SEC EDGAR ↗

6:43 AM ET Form 4
Insider Buying

AgomAb Therapeutics Insider David R. Epstein Buys $88.6K of Stock

David R. Epstein bought 14,960 shares of AgomAb Therapeutics NV at $5.75 to $6.02 a share (average $5.92) in 3 transactions, worth $88.6K in total on Nov 13, 2026. Shares held after the trade: 54,980 (+9.9%).

Value
$88.6K
Shares
14,960
Average price
$5.92
Holding change
+9.9%
Trade date
Nov 13, 2026
6:39 AM ET Form 4
Insider Buying

AgomAb Therapeutics Insider David R. Epstein Buys $104K of Stock

David R. Epstein bought 15,000 shares of AgomAb Therapeutics NV at $6.81 to $6.98 a share (average $6.90) in 3 transactions, worth $104K in total on Nov 5, 2026. Shares held after the trade: 40,000 (+14.3%).

Value
$104K
Shares
15,000
Average price
$6.90
Holding change
+14.3%
Trade date
Nov 5, 2026
8:15 AM ET Form 4
Insider Buying

AgomAb Therapeutics Insider David R. Epstein Buys $88.8K of Stock

David R. Epstein bought 10,000 shares of AgomAb Therapeutics NV at $8.86 to $8.90 a share (average $8.88) in 2 transactions, worth $88.8K in total on Oct 21, 2026. Shares held after the trade: 25,000 (+25.0%).

Value
$88.8K
Shares
10,000
Average price
$8.88
Holding change
+25.0%
Trade date
Oct 21, 2026
8:01 AM ET Form 4
Insider Buying

AgomAb Therapeutics Insider David R. Epstein Buys $44.5K of Stock

David R. Epstein bought 5,000 shares of AgomAb Therapeutics NV at $8.90 a share, worth $44.5K in total on Oct 8, 2026. Shares held after the trade: 15,000 (+50.0%).

Value
$44.5K
Shares
5,000
Price
$8.90
Holding change
+50.0%
Trade date
Oct 8, 2026
8:57 AM ET Form 4
Insider Buying

AgomAb Therapeutics Insider David R. Epstein Buys $86.3K of Stock

David R. Epstein bought 10,000 shares of AgomAb Therapeutics NV at $8.57 to $8.70 a share (average $8.63) in 2 transactions, worth $86.3K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 10,000 (+100.0%).

Value
$86.3K
Shares
10,000
Average price
$8.63
Holding change
+100.0%
Trade date
Oct 5, 2026 to Oct 6, 2026
8:47 AM ET Form 4
Insider Buying

AgomAb Therapeutics CFO Pierre Thadee Victor Kemula Buys $85.9K of Stock

Pierre Thadee Victor Kemula, CFO, bought 10,000 shares of AgomAb Therapeutics NV at $8.54 to $8.67 a share (average $8.59) in 3 transactions, worth $85.9K in total on Oct 6, 2026. Shares held after the trade: 10,000 (+25.0%).

Value
$85.9K
Shares
10,000
Average price
$8.59
Role
CFO
Holding change
+25.0%
Trade date
Oct 6, 2026
8:07 AM ET Form 4
Insider Buying

AgomAb Therapeutics CEO Tim Jasper Knotnerus Buys $94.4K of Stock

Tim Jasper Knotnerus, CEO, bought 11,000 shares of AgomAb Therapeutics NV at $8.48 to $8.70 a share (average $8.58) in 2 transactions, worth $94.4K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 21,823 (+29.7%).

Value
$94.4K
Shares
11,000
Average price
$8.58
Role
CEO
Holding change
+29.7%
Trade date
Oct 5, 2026 to Oct 6, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.